Illumina, Inc.

NasdaqGS:ILMN 株式レポート

時価総額：US$28.4b

Illumina 将来の成長

Future 基準チェック /26

Illumina利益と収益がそれぞれ年間12.5%と6.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に25.8% 13.3%なると予測されています。

主要情報

12.5%

収益成長率

13.29%

EPS成長率

Life Sciences 収益成長18.6%
収益成長率6.6%
将来の株主資本利益率25.79%
アナリストカバレッジ

Good

最終更新日13 Aug 2026

今後の成長に関する最新情報

Recent updates

ナラティブ更新 • Aug 10

ILMN: Strong Clinical Sequencing Trends Will Likely Fail To Offset Execution Risks

Illumina's updated fair value estimate rises from $87.05 to $126.91 as analysts lift price targets across the sector, citing stronger Q2 results, solid instrument placements that may support consumables usage, and improving sentiment around clinical sequencing and long term growth initiatives. Analyst Commentary Recent research coverage on Illumina points to a clear reset higher in price targets across much of Wall Street.
ナラティブ更新 • Jul 27

ILMN: Future Returns Will Depend On Clinical Sequencing Momentum Facing Legal Headwinds

The updated analyst price target for Illumina rises from about $147 to roughly $173 per share. This reflects analysts' use of higher sector multiples, modestly adjusted growth and profitability assumptions, and a generally more constructive view on diagnostics, genomics infrastructure, and AI supported research demand.
ナラティブ更新 • Jul 13

ILMN: Clinical Sequencing Momentum And Sector Funding Support A Fairly Balanced Outlook

The fair value estimate for Illumina has been raised from $185 to $200, reflecting analysts' higher $200 price targets and their view that the company remains a core genomics infrastructure provider, as sector research points to healthy demand trends and solid customer engagement. Analyst Commentary Recent Street research on Illumina points to an increasingly constructive stance from several bullish analysts, with multiple firms revisiting assumptions on demand, execution, and the role of the company in genomics and broader life sciences tools.
ナラティブ更新 • Jun 29

ILMN: Clinical Execution And Sector Funding Support A Cautiously Balanced Outlook

The analyst fair value estimate for Illumina has been lifted by $10 to $185, reflecting higher Street price targets and analyst expectations for stronger customer spending and margins, supported by recent research, survey feedback, and sector funding trends. Analyst Commentary Recent Street research around Illumina points to a more constructive tone, with several bullish analysts highlighting improving customer sentiment, sector funding trends, and clearer execution on the clinical side.
ナラティブ更新 • Jun 15

ILMN: Future Returns Will Hinge On Clinical Sequencing Momentum And Customer Stickiness

Narrative Update: Illumina The analyst price target underpinning this Illumina narrative has been raised from about $136 to $147, reflecting updated assumptions around customer stickiness, clinical sequencing momentum, and expectations for higher instrument and consumables spending highlighted in recent research. Analyst Commentary Recent research on Illumina reflects a mix of enthusiasm about the company’s position in sequencing markets and some ongoing caution around execution and valuation, with several major firms updating ratings and price targets.
ナラティブ更新 • Jun 01

ILMN: Clinical Momentum And Softer Competition Will Shape A Balanced Outlook

Analysts have lifted the fair value estimate for Illumina from $156.51 to $175.00, citing Street research that points to building clinical momentum, easing competitive concerns, and a series of higher price targets from several firms. Analyst Commentary Recent Street research on Illumina has tilted more constructive, with several bullish analysts pointing to improving clinical traction and a less intense competitive backdrop as key supports for the stock.
分析記事 • May 11

We Think That There Are Issues Underlying Illumina's (NASDAQ:ILMN) Earnings

Unsurprisingly, Illumina, Inc.'s ( NASDAQ:ILMN ) stock price was strong on the back of its healthy earnings report. We...
ナラティブ更新 • Apr 30

ILMN: Policy And Execution Risks Will Likely Outweigh Supportive Genome Consumable Pricing

Illumina's analyst-derived fair value has shifted modestly lower from $88.35 to $87.05 as analysts balance mixed target changes and view Roche's less aggressive genome pricing as a near term positive that supports assumptions for slightly stronger revenue growth and profit margins, along with a marginally lower future P/E. Analyst Commentary Street research around Illumina reflects a mix of views, with some analysts highlighting potential upside from competitive pricing developments and others trimming price targets in response to ongoing execution and valuation questions.
ナラティブ更新 • Apr 15

ILMN: Future Returns Will Depend On Pricing Power And 2026 Tools Demand

Analysts have kept the fair value estimate for Illumina steady at $136.11 per share, with a mix of recent price target increases and trims reflecting updated views on growth, profitability, and competitive pricing after Roche's latest genome sequencing announcement. Analyst Commentary Recent research suggests that views on Illumina are mixed, with the Roche Axelios pricing helping sentiment while target changes reflect different views on execution risk and growth visibility.
Seeking Alpha • Apr 10

Illumina: Competitive Threats Priced In

Summary Illumina fundamentals are improving, with FY26 expected to return to positive growth and enable operating leverage. Competition from Roche and others is a risk, but recent news appears priced in; shares have stabilized since the Roche Axelios reveal. FY26 guidance calls for 2% organic growth, EBIT margin expansion of 3% YoY, and further upside from the Somalogic acquisition. My DCF model supports a BUY rating with a $156 target price, implying 22% upside as margin expansion and NovaSeq X mix drive value. Read the full article on Seeking Alpha
ナラティブ更新 • Apr 01

ILMN: Future Returns Will Depend On 2026 Tools Demand And Competitive Pricing

Illumina's analyst price target nudged up to about $136, as analysts point to slightly firmer revenue growth assumptions, a steady profit margin outlook, and supportive read-through from recent Street research, including Roche's less aggressive genome pricing. Analyst Commentary Street research around Illumina has turned more active, with several firms adjusting price targets and updating views on genomics demand and competitive risks.
ナラティブ更新 • Mar 18

ILMN: Future Returns Will Hinge On China Recovery And 2026 Tools Demand

Illumina's updated analyst price target sits slightly higher at about $136, with analysts citing firmer revenue and margin assumptions, a modestly higher discount rate, and supportive recent commentary on competitive pricing for whole genome sequencing consumables. Analyst Commentary Recent Street research on Illumina reflects a mix of optimism and caution, with several firms adjusting price targets and reassessing the setup for the next couple of years.
ナラティブ更新 • Mar 04

ILMN: Policy And Execution Risks Will Likely Limit Benefits From Supportive Consumables Pricing

Illumina's analyst price targets have seen a modest upward reset, with a slightly higher fair value estimate of $88.35. This is supported by Street research that highlights firmer competitive pricing in sequencing consumables and a range of recent target revisions tied to updated views on growth, margins, discount rates, and future P/E assumptions.
ナラティブ更新 • Feb 18

ILMN: Policy And Execution Risks Will Likely Restrain Tools Thesis Upside

Illumina's updated analyst price target has increased to $87.97 from $80.00. This reflects analysts' mixed but generally more constructive views as they adjust for revised revenue growth, profit margin and future P/E assumptions following a series of recent target changes across the Street.
ナラティブ更新 • Feb 03

ILMN: Future Returns Will Depend On China Access And 2026 Execution

Narrative Update: Illumina Analyst Target Shift Our Analyst Price Target for Illumina moves modestly higher by about $4 per share as analysts cite updated views on revenue growth, profit margins, and future P/E multiples following a series of recent price target increases across the Street. Analyst Commentary Bullish and cautious voices are both weighing in on Illumina, and most of the recent activity centers on refreshed views for 2026, broader life science tools demand, and where valuation might settle after recent share moves.
ナラティブ更新 • Jan 20

ILMN: Future Returns Will Depend On China Recovery And Execution Through 2026

Analysts have raised their implied fair value for Illumina by about $12 to approximately $132 per share, reflecting updated views on revenue growth, profit margins and future P/E multiples, supported by a series of recent price target increases across the Street. Analyst Commentary Recent research updates cluster around higher price targets and mixed views on how reliably Illumina can deliver against those expectations.
ナラティブ更新 • Jan 06

ILMN: China Export Restrictions Will Likely Cap Upside Despite Cost Efficiencies

Analysts have raised their price targets on Illumina to a range of roughly $100 to $195, citing recovering end markets, healthier procedure and CapEx trends into 2026, and cost efficiencies highlighted in recent quarterly results, even as they continue to flag limited visibility and ongoing challenges in China. Analyst Commentary Recent research updates present a mixed picture for Illumina, with higher price targets sitting alongside ongoing questions around visibility, execution, and regional headwinds.
ナラティブ更新 • Dec 14

ILMN: China Export Risks Will Likely Limit Upside Despite Recent Optimism

Analysts raised our implied fair value estimate for Illumina by 7 dollars to 80 dollars per share. This reflects higher revenue growth and profit margin expectations following better than anticipated quarterly results and a series of upward price target revisions across the Street, despite lingering visibility concerns.
ナラティブ更新 • Nov 30

ILMN: Future Performance Will Rely On China Market and Operational Execution

Analysts have modestly increased their price targets for Illumina, with the fair value estimate rising by $2.11 per share to $119.84. This reflects confidence in the company’s recent quarterly performance and operational improvements despite ongoing sector headwinds.
ナラティブ更新 • Nov 16

ILMN: Future Momentum Will Depend On China Recovery And Efficiency Gains

Analysts have modestly raised their price target on Illumina, increasing fair value estimates from approximately $113.58 to $117.74. This reflects improved revenue growth and operational efficiency, despite mixed business visibility and regional challenges.
分析記事 • Nov 09

Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

The Illumina, Inc. ( NASDAQ:ILMN ) share price has done very well over the last month, posting an excellent gain of...
ナラティブ更新 • Nov 01

ILMN: Operational Progress Will Offset Ongoing China Exposure And Sector Uncertainties

Illumina's analyst price target has increased modestly, with the average rising from $111.95 to $113.58. Analysts cite stronger operational performance and revenue growth, even as the company faces ongoing sector and regional challenges.
ナラティブ更新 • Sep 04

Next-generation Sequencing Will Expand Clinical Capabilities Despite Risks

Illumina’s unchanged analyst price target reflects a balance between optimism for sector-leading EPS growth and resilience in consumables, and caution around persistent funding pressures, regulatory risks, and macroeconomic uncertainties, resulting in a maintained fair value of $111.95. Analyst Commentary Mixed quarterly performance prompted both positive and conservative price target adjustments, with solid earnings and guidance raises offset by ongoing academic funding pressures.
分析記事 • Aug 31

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Key Insights Illumina's estimated fair value is US$107 based on 2 Stage Free Cash Flow to Equity Current share price of...

業績と収益の成長予測

NasdaqGS:ILMN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20285,2661,0631,2301,40715
12/31/20274,9118911,0821,31218
12/31/20264,6257608981,13518
6/28/20264,4948249311,095N/A
3/29/20264,3938539741,128N/A
12/28/20254,3438509311,079N/A
9/28/20254,2887031,0071,122N/A
6/29/20254,2841,2571,0311,154N/A
3/30/20254,337-9668761,000N/A
12/29/20244,372-1,223709837N/A
9/29/20244,390-1,585547697N/A
6/30/20244,429-3,044358520N/A
3/31/20244,493-1,290367545N/A
12/31/20234,504-1,161283478N/A
10/1/20234,465-1,125169401N/A
7/2/20234,461-4,186-224210N/A
4/2/20234,448-4,487-228230N/A
1/1/20234,584-4,404-74392N/A
10/2/20224,700-4,15379527N/A
7/3/20224,693-2053307N/A
4/3/20224,656701208435N/A
1/2/20224,526762337545N/A
10/3/20214,280907469669N/A
7/4/20213,9667698981,094N/A
4/4/20213,4736308901,081N/A
1/3/20213,2396568911,080N/A
9/27/20203,2386389331,117N/A
6/28/20203,3516931,0461,231N/A
3/29/20203,556942N/A1,134N/A
12/29/20193,5431,002N/A1,051N/A
9/29/20193,458973N/A908N/A
6/30/20193,405938N/A933N/A
3/31/20193,397851N/A1,085N/A
12/30/20183,333826N/A1,142N/A
9/30/20183,243684N/A1,136N/A
7/1/20183,103648N/A1,079N/A
4/1/20182,936567N/A962N/A
12/31/20172,752725N/A875N/A
10/1/20172,594775N/A843N/A
7/2/20172,487741N/A784N/A
4/2/20172,424730N/A848N/A
1/1/20172,398454N/A779N/A
10/2/20162,371440N/A757N/A
7/3/20162,314430N/A762N/A
4/3/20162,253415N/A692N/A
1/3/20162,220462N/A786N/A
9/27/20152,141510N/A560N/A

アナリストによる今後の成長予測

収入対貯蓄率: ILMNの予測収益成長率 (年間12.5% ) は 貯蓄率 ( 3.7% ) を上回っています。

収益対市場: ILMNの収益 ( 12.5% ) US市場 ( 16.9% ) よりも低い成長が予測されています。

高成長収益: ILMNの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: ILMNの収益 ( 6.6% ) US市場 ( 12.9% ) よりも低い成長が予測されています。

高い収益成長: ILMNの収益 ( 6.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ILMNの 自己資本利益率 は、3年後には高くなると予測されています ( 25.8 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/19 16:59
終値2026/08/19 00:00
収益2026/06/28
年間収益2025/12/28

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Illumina, Inc. 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。47

アナリスト機関
Jasper HellwegArgus Research Company
Catherine Ramsey SchulteBaird
Robert BambergerBaird